----

----

```
FORM 1O-QSB/AAmendment No. 1  xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the quarterly period ended September 30, 2005  oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from ________ to ________       Commission File Number: 0-21284 STATSURE DIAGNOSTIC SYSTEMS, INC. FORMERLYSALIVA DIAGNOSTIC SYSTEMS, INC.(Exact name of small business issuer as specified in its charter) Delaware91-1549305(State or other jurisdiction(I.R.S. Employerof incorporation or organization)Identification No.) 1 Clarks Hill Rd.Framingham, MA. 01702(Address of principal executive offices and zip code) (508) 872-2625(Issuer's telephone number including area code) Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes x No o The number of shares outstanding of the Registrant's Common Stock as of November 10, 2005, 31,769,491 shares. Transitional Small Business Disclosure Format (check one): Yes o No x 
```

----

**Explanatory      Note**

| a)   | to                account for the beneficial conversion feature on certain convertible                debentures issued using the effective interest                method. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| b)   | to                properly record the amount of compensation expense for 1,100,000                stock                options granted to certain employees for                the nine month period ended September 30,                2005. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| c)   | to                record the proper expense for warrants issued for services rendered                to the                Company which was previously                discounted. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                          |                                                                           | PAGE   |
|-----------------------------------------------|--------------------------------------------------------------------------------|--------|
| PART                  I FINANCIAL INFORMATION |                                                                           |
|                                          |                                                                           |   |
| Item                  1.                      | Financial                  Statements                                          |   |
|                                          |                                                                           |   |
|                                          | Balance                  sheets - September 30, 2005 (unaudited) and           |   |
|                                          | December                  31, 2004                                             | 4      |
|                                          |                                                                           |   |
|                                          | Statements                  of Operations - Three Months and Nine Months Ended |   |
|                                          | September                  30, 2005 and 2004 (unaudited)                       | 5      |
|                                          |                                                                           |   |
|                                          | Statements                  of Cash Flows- Nine Months Ended                   |   |
|                                          | September                  30, 2005 and 2004 (unaudited)                       | 6      |
|                                          |                                                                           |   |
|                                          | Notes                  to Financial Statements (unaudited)                     | 7      |
|                                          |                                                                           |   |
| Item                  2.                      | Management's                  Discussion and Analysis of Financial Condition   |   |
|                                          | And                  Plan of Operation                                         | 16     |
|                                          |                                                                           |   |
| Item                  3.                      | Controls                  and Procedures                                       | 26     |
|                                          |                                                                           |   |
| PART                  II OTHER INFORMATION    |                                                                           |
|                                          |                                                                           |   |
| Item                  1.                      | Legal                  Proceedings                                             | 27     |
|                                          |                                                                           |   |
| Item                  2.                      | Changes                  in Securities                                         | 27     |
|                                          |                                                                           |   |
| Item                  3.                      | Defaults                  Upon Senior Securities                               | 27     |
|                                          |                                                                           |   |
| Item                  4.                      | Submission                  of Matters to a Vote of Security Holders           | 27     |
|                                          |                                                                           |   |
| Item                  5.                      | Other                  Information                                             | 27     |
|                                          |                                                                           |   |
| Item                  6.                      | Exhibits                                                                       | 28     |
|                                          |                                                                           |   |
| Signatures.                                   | 29                                                                             |
|                                          |                                                                           |   |
| Certifications                                |                                                                           |

----

**PART      I FINANCIAL INFORMATION**

**Item      1. FINANCIAL STATEMENTS**

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS, INC.**

**BALANCE      SHEETS**

|                                                                                                                                                                             |   | **September                30, 2005****(Unaudited)** |        | **December 31, 2004** |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------|-------------|---------------------------------|--------|
|                                                                                                                                                                             |   | **(Restated)**                                       |        |                            |   |
| **ASSETS**                                                                                                                                                                       |   |                                                 |        |                            |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |
| CURRENT                ASSETS:                                                                                                                                                   |   |                                                 |        |                            |   |
| Cash                and cash equivalents                                                                                                                                         |   | $                                                    | 20,861      |                            | $      | 148,630 |   |
| Accounts                receivable, net of allowance for doubtful accounts of $107,477 and                $                55,495 for both 2005 and 2004                         |   |                                                 | 120,353     |                            |   | 248,279 |   |
| Inventories                                                                                                                                                                      |   |                                                 | 70,313      |                            |   | 102,027 |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| Total                current assets                                                                                                                                              |   |                                                 | 211,527     |                            |   | 498,936 |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| Property                and equipment, net of accumulated depreciation of $549,038 (2005)                and                $518,675 (2004)                                      |   |                                                 | 104,345     |                            |   | 73,269 |   |
| Equipment                under construction                                                                                                                                      |   |                                                 | 664,401     |                            |   | 603,111 |   |
| Patents                and trademarks, net of accumulated amortization of $123,109(2005)                 and                $115,220 (2004)                                 |   |                                                 | 55,757      |                            |   | 62,046 |   |
| Deferred                costs, less accumulated amortization of $229,744 (2005)                and                $141,600 (2004)                                                |   |                                                 | 242,256     |                            |   | 170,400 |   |
| Deposits                                                                                                                                                                         |   |                                                 | 13,500      |                            |   | 800 |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| TOTAL                ASSETS                                                                                                                                                      |   | $                                                    | 1,291,786   |                            | $      | 1,408,562 |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| **LIABILITIES                AND SHAREHOLDERS’ EQUITY**                                                                                                                    |   |                                                 |             |                            |   |  |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| CURRENT                LIABILITIES:                                                                                                                                              |   |                                                 |             |                            |   |  |   |
| Bank                overdraft                                                                                                                                                    |   | $                                                    | —     |                            | $      | 26,953 |   |
| Note                payable - shareholders                                                                                                                                       |   |                                                 | 6,624       |                            |   | 243,398 |   |
| Accounts                payable                                                                                                                                                  |   |                                                 | 70,911      |                            |   | 129,222 |   |
| Customer                advances                                                                                                                                                 |   |                                                 | 455         |                            |   | 18,465 |   |
| Accrued                expenses                                                                                                                                                  |   |                                                 | 262,700     |                            |   | 356,081 |   |
| Accrued                payroll expense to officers                                                                                                                               |   |                                                 | 180,818     |                            |   | 161,250 |   |
| Payroll                and payroll taxes payable                                                                                                                                 |   |                                                 | 62,415      |                            |   | 70,078 |   |
| Debentures                payable - net of discount                                                                                                                              |   |                                                 | 61,449      |                            |   | — |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| Total                current liabilities                                                                                                                                         |   |                                                 | 645,372     |                            |   | 1,005,447 |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| LONG-TERM                DEBT                                                                                                                                                    |   |                                                 |        |                            |   |   |   |
| Note                payable - shareholder                                                                                                                                        |   |                                                 | 1,932,099   |                            |   | 2,069,839 |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| TOTAL                LIABILITIES                                                                                                                                                 |   |                                                 | 2,577,471   |                            |   | 3,075,286 |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| COMMITMENTS                AND CONTINGENCIES                                                                                                                                     |   |                                                 |             |                            |   |  |   |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| SHAREHOLDERS’                DEFICIT:                                                                                                                                      |   |                                                 |        |                            |   |   |   |
| Series                1998-B Convertible Preferred Stock: 1,645 shares authorized, none                issued                and outstanding                                     |   |                                                 | —     |                            |   | — |   |
| Common                stock, $.001 par value, 50,000,000 shares authorized, issued and                outstanding: 31,769,491 shares (2005) and 30,509,491                (2004) |   |                                                 | 31,769      |                            |   | 30,509 |   |
| Additional                paid-in capital                                                                                                                                        |   |                                                 | 44,721,716  |                            |   | 42,073,056 |   |
| Less:                Deferred Compensation                                                                                                                                       |   |                                                 | (134,747    | )                               |   | — |   |
| Accumulated                deficit                                                                                                                                               |   |                                                 | (45,904,423 | )                               |   | (43,770,289 | ) |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
| TOTAL                SHAREHOLDERS’ DEFICIT                                                                                                                                 |   |                                                 | (1,285,685  | )                               |   | (1,666,724 | ) |
|                                                                                                                                                                             |   |                                                 |        |                            |   |   |   |
|  TOTAL                LIABILITIES AND SHAREHOLDERS’                DEFICIT                                                                                            |   | $                                                    | 1,291,786   |                            | $      | 1,408,562 |   |

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS, INC.**

**STATEMENTS      OF OPERATIONS**

**(Unaudited)**

|                                                             |   | **Three                Months Ended September 30,** |       | **Nine                Months Ended September 30,** |   |
|------------------------------------------------------------------|--------|-----------------------------------------------------|------------|----------------------------------------------------|--------|
|                                                             |   | **2005**                                            |       | **2004**                                           |   | **2005** |   | **2004** |   |
| REVENUES:                                                        |   | RESTATED                                            |       |                                               |   | RESTATED |   |   |   |
| Product                Sales                                     |   | $                                                   | 204,846    |                                               | $      | 392,915 |   | $ | 645,853 |   | $ | 1,048,474 |   |
| Royalty                Income                                    |   |                                                | -          |                                               |   | - |   |   | 546 |   |   | 922 |   |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
|                                                             |   |                                                | 204,846    |                                               |   | 392,915 |   |   | 646,399 |   |   | 1,049,396 |   |
| COST                OF PRODUCTS SOLD                             |   |                                                | 75,500     |                                               |   | 128,987 |   |   | 226,240 |   |   | 370,251 |   |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| Gross                profit                                      |   |                                                | 129,346    |                                               |   | 263,928 |   |   | 420,159 |   |   | 679,145 |   |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| OPERATING                EXPENSES:                               |   |                                                |            |                                               |   |  |   |   |  |   |   |  |   |
| Research                and development                          |   |                                                | 102,449    |                                               |   | 35,925 |   |   | 264,005 |   |   | 400,925 |   |
| Selling,                general and administrative               |   |                                                | 227,300    |                                               |   | 136,845 |   |   | 1,844,124 |   |   | 288,905 |   |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
|                                                             |   |                                                | 329,749    |                                               |   | 172,770 |   |   | 2,108,129 |   |   | 689,830 |   |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| (Loss)                income from operations                     |   |                                                | (200,403   | )                                                  |   | 91,158 |   |   | (1,687,970 | ) |   | (10,685 | ) |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| OTHER                INCOME (EXPENSES):                          |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| Interest                expense-net                              |   |                                                | (92,559    | )                                                  |   | (80,299 | ) |   | (260,816 | ) |   | (236,782 | ) |
| Interest                expense on beneficial conversion feature |   |                                                | (36,309    | )                                                  |   | - |   |   | (121,449 | ) |   | - |   |
| Financing                costs                                   |   |                                                | (21,300    | )                                                  |   | - |   |   | (63,899 | ) |   | - |   |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| Total                other income (expenses):                    |   |                                                | (150,168   | )                                                  |   | (80,299 | ) |   | (446,164 | ) |   | (236,782 | ) |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| NET                (LOSS) INCOME TO COMMON SHAREHOLDERS          |   | $                                                   | (350,571   | )                                                  | $      | 10,859 |   | $ | (2,134,134 | ) | $ | (247,467 | ) |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| NET                LOSS PER SHARE:                               |   |                                                |            |                                               |   |  |   |   |  |   |   |  |   |
| BASIC                AND DILUTED                                 |   | $                                                   | (0.01      | )                                                  | $      | (0.00 | ) | $ | (0.07 | ) | $ | (0.01 | ) |
|                                                             |   |                                                |       |                                               |   |   |   |   |   |   |   |   |   |
| WEIGHTED                AVERAGE NUMBER OF SHARES OUTSTANDING:    |   |                                                |            |                                               |   |  |   |   |  |   |   |  |   |
| BASIC                AND DILUTED                                 |   |                                                | 31,720,578 |                                               |   | 30,509,700 |   |   | 31,335,938 |   |   | 30,509,700 |   |

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS, INC.**

**STATEMENTS      OF CASH FLOWS**

**(Unaudited)**

|                                                                                                                                                                                                                                                                                                      |   | **Nine Months Ended September                30,** |       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------|------------|
|                                                                                                                                                                                                                                                                                                      |   | **2005**                                                          |       | **2004** |   |
|                                                                                                                                                                                                                                                                                                      |   | **(Restated)**                                                    |       |   |   |
| OPERATING                ACTIVITIES:                                                                                                                                                                                                                                                                      |   |                                                         |       |   |   |
| Net                loss                                                                                                                                                                                                                                                                                   |   | $                                                                 | (2,134,134 | ) | $ | (247,467 | ) |
| Adjustments                to reconcile net loss to net cash (used in) operating                activities:                                                                                                                                                                                               |   |                                                              |       |   |   |   |   |
| Depreciation                and amortization                                                                                                                                                                                                                                                              |   |                                                              | 38,252     |   |   | 28,215 |   |
| Bad                debt expense                                                                                                                                                                                                                                                                           |   |                                                              | 51,982     |   |   | — |   |
| Amortization                of deferred costs                                                                                                                                                                                                                                                             |   |                                                              | 88,144     |   |   | 63,899 |   |
| Warrants                issued for recruiting services                                                                                                                                                                                                                                                    |   |                                                              | 399,622    |   |   | — |   |
| Options                granted to employees as compensation                                                                                                                                                                                                                                               |   |                                                              | 533,551    |   |   | — |   |
| Beneficial                conversion feature of convertible debentures                                                                                                                                                                                                                                    |   |                                                              | 121,449    |   |   | — |   |
| Changes                in assets and liabilities:                                                                                                                                                                                                                                                         |   |                                                              |       |   |   |   |   |
| Accounts                receivable                                                                                                                                                                                                                                                                        |   |                                                              | 75,944     |   |   | (123,007 | ) |
| Royalty                receivable                                                                                                                                                                                                                                                                         |   |                                                              | —    |   |   | 9,078 |   |
| Subscription                receivable                                                                                                                                                                                                                                                                    |   |                                                              | —    |   |   | 2,000 |   |
| Inventories                                                                                                                                                                                                                                                                                               |   |                                                              | 31,714     |   |   | (55,014 | ) |
| Other                current assets                                                                                                                                                                                                                                                                       |   |                                                              | (12,700    | ) |   | (37,586 | ) |
| Accounts                payable, accrued payroll expense to officers and accrued                expenses                                                                                                                                                                                                  |   |                                                              | 70,976     |   |   | 303,782 |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| Net                cash used in operating activities                                                                                                                                                                                                                                                      |   |                                                              | (735,200   | ) |   | (56,100 | ) |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| CASH                FLOWS FROM INVESTING ACTIVITIES:                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |  |   |
| Purchases                of property and equipment                                                                                                                                                                                                                                                        |   |                                                              | (122,729   | ) |   | (391,859 | ) |
| Acquisitions                of patents and trademarks                                                                                                                                                                                                                                                     |   |                                                              | (1,600     | ) |   | (13,710 | ) |
| Deferred                finance cost                                                                                                                                                                                                                                                                      |   |                                                              | (160,000   | ) |   | — |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| Net                cash used in investing activities                                                                                                                                                                                                                                                      |   |                                                              | (284,329   | ) |   | (405,569 | ) |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| CASH                FLOWS FROM FINANCING ACTIVITIES:                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |  |   |
| Cash                overdraft                                                                                                                                                                                                                                                                             |   |                                                              | (26,953    | ) |   | — |   |
| Proceeds                from shareholder loans                                                                                                                                                                                                                                                            |   |                                                              | 30,000     |   |   | 1,335,858 |   |
| Proceeds                from issuance of debentures                                                                                                                                                                                                                                                       |   |                                                              | 1,510,000  |   |   | — |   |
| Repayments                of shareholder loans                                                                                                                                                                                                                                                            |   |                                                              | (623,287   | ) |   | (879,657 | ) |
| Proceeds                from issuance of common stock                                                                                                                                                                                                                                                     |   |                                                              | 2,000      |   |   | — |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| Net                cash provided by financing activities                                                                                                                                                                                                                                                  |   |                                                              | 891,760    |   |   | 456,201 |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| NET                DECREASE IN CASH AND CASH EQUIVALENTS                                                                                                                                                                                                                                                  |   |                                                              | (127,769   | ) |   | (5,468 | ) |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| CASH                AND CASH EQUIVALENTS, BEGINNING OF PERIOD                                                                                                                                                                                                                                             |   |                                                              | 148,630    |   |   | 24,182 |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| CASH                AND CASH EQUIVALENTS, END OF PERIOD                                                                                                                                                                                                                                                   |   | $                                                                 | 20,861     |   | $ | 18,714 |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| SUPPLEMENTAL                DISCLOSURE OF CASH FLOW INFORMATION:                                                                                                                                                                                                                                          |   |                                                              |       |   |   |   |   |
| Cash                paid during the period for interest                                                                                                                                                                                                                                                   |   | $                                                                 | —    |   | $ | 124 |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| Cash                paid during the period for taxes                                                                                                                                                                                                                                                      |   | $                                                                 | 830        |   | $ | 1,428 |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| SUPPLEMENTAL                DISCLOSURE OF NON-CASH FLOW INFORMATION:                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| During                the nine month periods ended September 30, 2005 and 2004, the                previous year’s balance of                accrued interest of $228,773 and $68,265, respectively, for a                shareholder’s loan was added to the loan balance as principal. |   | $                                                                 | 228,773    |   | $ | 143,128 |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| During                the nine month period ended September 30, 2005, 1,000,000 shares                of common                stock were issued for a warrant conversion at $.01 per share. Payment                due                of $10,000 was offset to a note payable to this stockholder.       |   | $                                                                 | 10,000     |   | $ | — |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| Conversion                of debentures payable into common stock                                                                                                                                                                                                                                         |   | $                                                                 | 60,000     |   | $ | — |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| During                the nine month period ended September 30, 2005, 1,100,000 options                were                issued to employees as compensation                                                                                                                                            |   | $                                                                 | 668,300    |   | $ | — |   |
|                                                                                                                                                                                                                                                                                                      |   |                                                              |       |   |   |   |   |
| During                the nine month period ended September 30, 2005, debenture in the                amount of                $1,510,000 were sold and resulted in beneficial conversion charge                of                $1,510,000                                                              |   | $                                                                 | 1,510,000  |   | $ | — |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**SEPTEMBER        30, 2005**

**(UNAUDITED)**

**1.      Description of Business/Basis of Presentation**

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**NOTES      TO FINANCIAL STATEMENTS**

**SEPTEMBER      30, 2005**

**(UNAUDITED)**

**2. **
**Substantial      Doubt Regarding Ability To Continue As A Going Concern**

**3.      Summary Of Significant Accounting Policies**

***Basis      of Presentation:***

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**SEPTEMBER        30, 2005**

**(UNAUDITED)**

**3.      Summary Of Significant Accounting Policies (continued)**

**4.      Restatement**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**SEPTEMBER        30, 2005**

**(UNAUDITED)**

|                                                                |   | September                30, 2005 |        |
|---------------------------------------------------------------------|--------|-----------------------------------|-------------|
|                                                                |   | As                reported        |        | As                Restated |   |
| BALANCE                SHEET:                                       |   |                              |        |   |   |
| Current                portion of debenture payable net of discount |   | $                                 | 241,667     |   | $ | 61,449 |   |
| Total                current liabilities                            |   |                              | 825,590     |   |   | 645,372 |   |
| Debentures                payable-net of discount                   |   |                              | 1,208,333   |   |   | - |   |
| Additional                paid-in capital                           |   |                              | 43,368,096  |   |   | 44,721,716 |   |
| Less:                Deferred compensation                          |   |                              | (722,720    | ) |   | (134,747 | ) |
| Accumulated                deficit                                  |   |                              | (45,351,381 | ) |   | (45,904,423 | ) |

|                                                                                      |   | For                  the three months endedSeptember                  30, 2005 |                 | For                  the nine months endedSeptember                  30, 2005 |   |
|-------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------|----------------------|-------------------------------------------------------------------------------|--------|
|                                                                                      |   | As                  reported                                                   |                 | As                  Restated                                                  |   | As                  reported |   | As                  Restated |   |
| STATEMENT                  OF OPERATIONS:                                                 |   |                                                                           |                 |                                                                          |   |   |   |   |   |   |   |   |   |
| Selling,                  general and administrative expense                              |   | $                                                                              | 339,644              |                                                                          | $      | 227,300 |   | $ | 1,412,531 |   | $ | 1,844,124 |   |
| Loss                  from operations                                                     |   |                                                                           | (312,747             | )                                                                             |   | (200,403 | ) |   | (1,256,377 | ) |   | (1,687,970 | ) |
| Interest                  expense-net                                                     |   |                                                                           | (113,859             | )                                                                             |   | (92,559 | ) |   | (324,715 | ) |   | (260,816 | ) |
| Interest                  expense on beneficial  conversion                  feature |   |                                                                           | -                    |                                                                          |   | (36,309 | ) |   | - |   |   | (121,449 | ) |
| Financing                  costs                                                          |   |                                                                           | -                    |                                                                          |   | (21,300 | ) |   | - |   |   | (63,899 | ) |
| Net                  loss to common shareholders                                          |   |                                                                           | (426,606             | )                                                                             |   | (350,571 | ) |   | (1,581,092 | ) |   | (2,134,134 | ) |
| Net                  loss per share-basic and diluted                                     |   |                                                                           | (                  - | )                                                                             |   | (.01 | ) |   | (.05 | ) |   | (.07 | ) |

|                                                                                                |   | For                the nine months endedSeptember                30, 2005 |       |
|-----------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------------------------|------------|
|                                                                                                |   | As                reported                                                |       | As                Restated |   |
| STATEMENT                OF CASH FLOWS:                                                             |   |                                                                      |       |   |   |
| Net                loss                                                                             |   | $                                                                         | (1,581,092 | ) | $ | (2,134,134 | ) |
| Warrants                issued for recruiting services                                              |   |                                                                      | 280,000    |   |   | 399,622 |   |
| Beneficial                conversion feature of convertible debentures                              |   |                                                                      | -          |   |   | 121,449 |   |
| Options                issued to employee as compensation                                           |   |                                                                      | 221,580    |   |   | 533,551 |   |
| SUPPLEMENTAL                DISCLOSURE OF NON-CASH FLOW ACTIVITIES                                  |   |                                                                      |       |   |   |   |   |
| Discount                related to beneficial conversion feature of convertible                debt |   |                                                                      | -          |   |   | 1,510,000 |   |
| Options                issued to employees as compensation                                          |   |                                                                      | 944,300    |   |   | 668,300 |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**SEPTEMBER        30, 2005**

**(UNAUDITED)**

|                                                                                                                                                                                                    |   |  For              the three months endedSeptember                30, 2005 |     | For                the nine months endedSeptember                30, 2005  |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------|----------|---------------------------------------------------------------------------------|--------|
|                                                                                                                                                                                                    |   | As                Reported                                                     |     | As                Restated                                                      |   | As                Reported |   | As                Restated |   |
|                                                                                                                                                                                                    |   |                                                                           |     |                                                                            |   |   |   |   |   |
| Net                loss to common shareholders                                                                                                                                                          |   | $                                                                              | (426,606 | )                                                                               | $      | (350,571 | ) | $ | (1,581,092 | ) | $ | (2,134,134 | ) |
| Add:                Stock-based employee compensation expense included in reported net                loss,                net of related tax affects                                                   |   |                                                                           | 92,586   |                                                                            |   | (19,758 | ) |   | 221,580 |   |   | 533,551 |   |
| Deduct:                Total stock-based employee compensation expense determined under                fair                value based method for all awards, net of related tax                affects |   |                                                                           | (90,428  | )                                                                               |   | (253,938 | ) |   | (213,266 | ) |   | (1,021,991 | ) |
|                                                                                                                                                                                                    |   |                                                                           |     |                                                                            |   |   |   |   |   |   |   |   |   |
| Pro                forma                                                                                                                                                                                |   | $                                                                              | (424,448 | )                                                                               | $      | (624,267 | ) | $ | (1,572,778 | ) | $ | (2,622,574 | ) |
|                                                                                                                                                                                                    |   |                                                                           |     |                                                                            |   |   |   |   |   |   |   |   |   |
| Basic                and diluted net loss per share                                                                                                                                                     |   |                                                                           |     |                                                                            |   |   |   |   |   |   |   |   |   |
| As                reported                                                                                                                                                                              |   | $                                                                              | (0.01    | )                                                                               | $      | (0.01 | ) | $ | (0.05 | ) | $ | (0.07 | ) |
| Pro                forma                                                                                                                                                                                |   |                                                                           | (0.01    | )                                                                               |   | (0.02 | ) |   | (0.05 | ) |   | (0.08 | ) |

**5.      Inventories**

|                          |   | **September                30, 2005** |       | December                31, 2004 |   |
|-------------------------------|--------|---------------------------------------|------------|----------------------------------|--------|
|                          |   |                                  |       |                             |   |
| Raw                materials  |   | **$**                                 | **66,793** |                             | $      | 87,407 |   |
| Finished                goods |   |                                  | **3,520**  |                             |   | 14,620 |   |
|                          |   | **$**                                 | **70,313** |                             | $      | 102,027 |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**SEPTEMBER        30, 2005**

**(UNAUDITED)**

**6.      Accounts Receivable**

**7.      Equipment Under Construction**

**8.      Accrued Expenses**

|                                     |   | **September                30, 2005** |        | December                31, 2004 |   |
|------------------------------------------|--------|---------------------------------------|-------------|----------------------------------|--------|
| Accrued                interest          |   | **$**                                 | **260,817** |                             | $      | 228,773 |   |
| Accrued                legal expense     |   |                                  | **-**       |                             |   | 112,500 |   |
| Other                accrued liabilities |   |                                  | **1,883**   |                             |   | 14,808 |   |
|                                     |   | **$**                                 | **262,700** |                             | $      | 356,081 |   |

**9.      Geographic Area Information**

|                          |   | **For the three months****ended                September 30,** |        | **For                the nine months****ended                September 30,** |   |
|-------------------------------|--------|-------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------------|--------|
|                          |   | **2005**                                                                      |        | 2004                                                                         |   | **2005** |   | 2004 |   |
| United                States  |   | **$**                                                                         | **600**     |                                                                         | $      | 182,136 |   | **$** | **152,098** |   | $ | 529,956 |   |
| United                Kingdom |   |                                                                          | **147,373** |                                                                         |   | 163,932 |   |   | **376,777** |   |   | 371,932 |   |
| Africa                        |   |                                                                          | **12,932**  |                                                                         |   | 44,650 |   |   | **61,670** |   |   | 111,550 |   |
| Other                         |   |                                                                          | **43,941**  |                                                                         |   | 2,197 |   |   | **55,308** |   |   | 35,036 |   |
|                          |   |                                                                          |        |                                                                         |   |   |   |   |   |   |   |   |   |
|                          |   | **$**                                                                         | **204,846** |                                                                         | $      | 392,915 |   | **$** | **645,853** |   | $ | 1,048,474 |   |

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**NOTES      TO FINANCIAL STATEMENTS**

**SEPTEMBER      30, 2005**

**(UNAUDITED)**

**10.      Deferred Costs**

**11.      Debenture Payable**

**12.      Financing from Shareholders**

**13.      Shareholders’ Equity Transactions**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**SEPTEMBER        30, 2005**

**(UNAUDITED)**

**14.      Contingencies **

| Payments                Due by Period |   | Future                Payments |      |
|---------------------------------------|--------|--------------------------------|-----------|
| <1                year             |   | $                              | 281,716   |   |
| 1-3                years              |   |                           | 2,959,515 |   |
| 4th                year               |   |                           | 241,667   |   |
|                                  |   | $                              | 3,482,898 |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**SEPTEMBER        30, 2005**

**(UNAUDITED)**

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**SEPTEMBER      30, 2005**

**ITEM      2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF      OPERATION**

**GENERAL**

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**SEPTEMBER      30, 2005**

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**SEPTEMBER      30, 2005**

**CRITICAL      ACCOUNTING POLICIES AND ESTIMATES**

**Restatement      of Financial Statements**

|  | a) | to                account for the beneficial conversion feature on certain convertible                debentures issued using the effective interest                method. |
|--|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | b) | to                properly record the amount of compensation expense for 1,100,000                stock                options granted to certain employees for                the nine month period ended September 30,                2005. |
|--|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | c) | to                record the proper expense for warrants issued for services rendered                to the                Company which was previously                discounted. |
|--|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | a) | Subsequent                to the filing of form 10-QSB for the three and nine month period                ended                September 30, 2005, the Company determined that the filing did not                reflect                a beneficial conversion feature on 9% convertible debentures issued                in                2005 as required under EITF 98-5 “Accounting for Convertible Securities                With Beneficial Conversion Features or Contingently Adjustable Conversion                Ratios”, as amended by EITF 00-27 “Application of Issue No. 98-5 to                Certain Convertible Instruments”. |
|--|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**SEPTEMBER        30, 2005**

|  | b) | The                Company revalued options granted to employees using FASB Interpretation                No. 28, Accounting for Stock Appreciation Rights and Other Variable                Stock                Option or Award Plans, an interpretation of APB Opinions No. 15 and                No. 25                (“FIN 28”). The Interpretation clarifies the accounting for compensation                related to variable stock options and specifies that compensation                should                be measured at the end of each period as the amount by which the                quoted                market value of the shares of the Company’s common stock covered by a                grant, exceeds the option price or value specified under the plan                and                should be accrued as a charge to expense over the periods the employee                performs the related services. Changes in the quoted market value                should                be reflected as an adjustment of accrued compensation and compensation                expense in the periods in which the changes occur until the date                the                number of shares and purchase price, if any, are both known. As a                result,                the compensation charge for these options for the nine months ended                September 30, 2005 has been restated to $533,551 from $221,580. The                result                of this restatement was to increase compensation expense by $311,971                and                to reduce and accordingly to reduce additional paid-in capital by                $311,971                for the nine month period ended September 30,                2005. |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | c) | Further,                the Company also revalued warrants issued during the first quarter                2005 as                payment for services rendered for which the Company had used a 30%                discount for various restriction. This revaluation increased related                expense to $399,622 from $280,000. The Company accounts for warrants                granted to its non-employee consultants using the fair value cost                in                accordance with SFAS 123 and EITF No. 96-18, “Accounting for Equity                Instruments That Are Issued to Other Than Employees”. The fair value of                warrants granted was estimated on the date of grant using the                Black-Scholes option-pricing model with the following weighted-average                assumptions: expected volatility of 200.4%, risk-free interest rate                of                3.71% and expected life of 4.93 years for the nine month period ended                September 30, 2005. The effect of this restatement was to increase                expenses and additional paid-in capital by                $119,622. |
|--|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                |   | September                30, 2005 |        |
|---------------------------------------------------------------------|--------|-----------------------------------|-------------|
|                                                                |   | As                reported        |        | As                Restated |   |
| BALANCE                SHEET:                                       |   |                              |        |   |   |
| Current                portion of debenture payable net of discount |   |                              | 241,667     |   |   | 61,449 |   |
| Total                current liabilities                            |   |                              | 825,590     |   |   | 645,372 |   |
| Debentures                payable-net of discount                   |   |                              | 1,208,333   |   |   | - |   |
| Additional                paid-in capital                           |   |                              | 43,368,096  |   |   | 44,721,716 |   |
| Less:                Deferred compensation                          |   |                              | (722,720    | ) |   | (134,747 | ) |
| Accumulated                deficit                                  |   |                              | (45,351,381 | ) |   | (45,904,423 | ) |

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**SEPTEMBER      30, 2005**

|                                                                            |   | For                the three months endedSeptember                30, 2005 |     | For                the nine months endedSeptember                30, 2005 |   |
|---------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------|----------|---------------------------------------------------------------------------|--------|
|                                                                            |   | As                reported                                                 |     | As                Restated                                                |   | As                reported |   | As                Restated |   |
| STATEMENT                OF OPERATIONS:                                         |   |                                                                       |     |                                                                      |   |   |   |   |   |
| Selling,                general and administrative expense                      |   | $                                                                          | 339,644  |                                                                      | $      | 227,300 |   | $ | 1,412,531 |   | $ | 1,844,124 |   |
| Loss                from operations                                             |   |                                                                       | (312,747 | )                                                                         |   | (200,403 | ) |   | (1,256,377 | ) |   | (1,687,970 | ) |
| Interest                expense-net                                             |   |                                                                       | (113,859 | )                                                                         |   | (92,559 | ) |   | (324,715 | ) |   | (260,816 | ) |
| Interest                expense on beneficial conversion                feature |   |                                                                       | -        |                                                                      |   | (36,309 | ) |   | - |   |   | (121,449 | ) |
| Financing                costs                                                  |   |                                                                       | -        |                                                                      |   | (21,300 | ) |   | - |   |   | (63,899 | ) |
| Net                loss to common shareholders                                  |   |                                                                       | (426,606 | )                                                                         |   | (350,571 | ) |   | (1,581,092 | ) |   | (2,134,134 | ) |

|                                                                                                |   | For                the nine months endedSeptember                30, 2005 |       |
|-----------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------------------------|------------|
|                                                                                                |   | As                reported                                                |       | As                Restated |   |
| STATEMENT                OF CASH FLOWS:                                                             |   |                                                                      |       |   |   |
| Net                loss                                                                             |   | $                                                                         | (1,581,092 | ) | $ | (2,134,134 | ) |
| Warrants                issued for recruiting services                                              |   |                                                                      | 280,000    |   |   | 399,622 |   |
| Beneficial                conversion feature of convertible debentures                              |   |                                                                      | -          |   |   | 121,449 |   |
| Options                issued to employee as compensation                                           |   |                                                                      | 221,580    |   |   | 533,551 |   |
| SUPPLEMENTAL                DISCLOSURE OF NON-CASH FLOW ACTIVITIES                                  |   |                                                                      |       |   |   |   |   |
| Discount                related to beneficial conversion feature of convertible                debt |   |                                                                      | -          |   |   | 1,510,000 |   |
| Options                issued to employees as compensation                                          |   |                                                                      | 944,300    |   |   | 668,300 |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**SEPTEMBER        30, 2005**

|                                                                                                                                                                                                    |   | For                the three months endedSeptember                30, 2005 |     | For                the nine months endedSeptember                30, 2005 |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------|----------|---------------------------------------------------------------------------|--------|
|                                                                                                                                                                                                    |   | As                Reported                                                 |     | As                Restated                                                |   | As                Reported |   | As                Restated |   |
|                                                                                                                                                                                                    |   |                                                                       |     |                                                                      |   |   |   |   |   |
| Net                loss to common shareholders                                                                                                                                                          |   | $                                                                          | (426,606 | )                                                                         | $      | (350,571 | ) | $ | (1,581,092 | ) | $ | (2,134,134 | ) |
| Add:                Stock-based employee compensation expense included in reported net                loss,                net of related tax affects                                                   |   |                                                                       | 92,586   |                                                                      |   | (19,758 | ) |   | 221,580 |   |   | 533,551 |   |
| Deduct:                Total stock-based employee compensation expense determined under                fair                value based method for all awards, net of related tax                affects |   |                                                                       | (90,428  | )                                                                         |   | (253,938 | ) |   | (213,266 | ) |   | (1,021,991 | ) |
|                                                                                                                                                                                                    |   |                                                                       |     |                                                                      |   |   |   |   |   |   |   |   |   |
| Pro                forma                                                                                                                                                                                |   | $                                                                          | (424,448 | )                                                                         | $      | (624,267 | ) | $ | (1,572,778 | ) | $ | (2,622,574 | ) |
|                                                                                                                                                                                                    |   |                                                                       |     |                                                                      |   |   |   |   |   |   |   |   |   |
| Basic                and diluted net loss per share                                                                                                                                                     |   |                                                                       |     |                                                                      |   |   |   |   |   |   |   |   |   |
| As                reported                                                                                                                                                                              |   | $                                                                          | (0.01    | )                                                                         | $      | (0.01 | ) | $ | (0.05 | ) | $ | (0.07 | ) |
| Pro                forma                                                                                                                                                                                |   |                                                                       | (0.01    | )                                                                         |   | (0.02 | ) |   | (0.05 | ) |   | (0.08 | ) |

**RESULTS      OF OPERATIONS**

**Revenues.**
** **

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**SEPTEMBER        30, 2005**

**Cost      of products sold**

**Research      and development expenses:**
** **
** **

| ·   | additional                HIV test clinical trial costs which amounted to $9,942 in the third                quarter of 2005 |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| ·   | additional                consulting costs associated with the Food and Drug Administration                PMA                submissions. These consultant costs totaled $92,507 in the third                quarter                of 2005. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Selling,      general and administrative expenses**

**Loss      from operations:**

**Other      expenses:**

**Income      taxes**
***.***

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**SEPTEMBER        30, 2005**

**LIQUIDITY      AND CAPITAL RESOURCES**

|                                     |   | **September                30, 2005** |         | December                31, 2004 |   |
|------------------------------------------|--------|---------------------------------------|--------------|----------------------------------|--------|
| Cash                and cash equivalents |   | **$**                                 | **20,861**   |                             | $      | 148,630 |   |
| Working                capital (deficit) |   |                                  | **(433,845** | **)**                            |   | (506,511 | ) |

| ·   | Legal                and accounting costs |
|--------------------|-------------------------------------------|

|   |   |
|--------|--------|

| ·   | Expenses                recorded for beneficial conversion features of convertible debt,                and |
|--------------------|-------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| ·   | Stock                and warrant issuance costs |
|--------------------|-------------------------------------------------|

|   |   |
|--------|--------|

| ·   | Consulting                expenses |
|--------------------|------------------------------------|

|   |   |
|--------|--------|

| ·   | Payroll                expenses |
|--------------------|---------------------------------|

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**SEPTEMBER        30, 2005**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**SEPTEMBER        30, 2005**

| Payments                Due by Period |   | Future                Payments |      |
|---------------------------------------|--------|--------------------------------|-----------|
| <1                year             |   | $                              | 281,716   |   |
| 1-3                years              |   |                           | 2,959,515 |   |
| 4th                year               |   |                           | 241,667   |   |
|                                  |   | $                              | 3,482,898 |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**SEPTEMBER        30, 2005**

**ITEM      3. CONTROLS AND PROCEDURES **

**EVALUATION      OF DISCLOSURE CONTROLS AND PROCEDURES**

**CHANGE      IN INTERNAL CONTROLS**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**SEPTEMBER        30, 2005**

**PART      II. OTHER INFORMATION**

**Item      1**
**.      LEGAL PROCEEDINGS**

**Item      2. **
**CHANGES      IN SECURITIES**

**ITEM      3. **
**DEFAULTS      UPON SENIOR SECURITIES**

**ITEM      4. **
**SUBMISSION      OF MATTERS TO A VOTE OF SECURITY HOLDERS**

**ITEM      5. **
**OTHER      INFORMATION**

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**SEPTEMBER      30, 2005**

**ITEM      6. EXHIBITS **

| **Exhibit** |    |                                                                                                                                                                                                                                                                                                                                                    |
|-------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |         |
| 11          |    | Earnings                per share                                                                                                                                                                                                                                                                                                                       |
|        |         |
| 31.1        |    | Certification                of Chief                Executive Officer                required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities                Exchange                Act of 1934, as amended.                                                                                                                                 |
|        |         |
| 31.2        |    | Certification                of Chief                Financial Officer                required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities                Exchange                Act of 1934, as amended.                                                                                                                                 |
|        |         |
| 32.1        |    | Certification                of Chief                Executive Officer                required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities                Exchange                Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant                to Section 906 of the Sarbanes-Oxley Act of 2002.                |
|        |         |
| 32.2        |    | Certification                of Chief                Financial Officer                required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities                Exchange                Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant                to Section 906 of the Sarbanes-Oxley Act of                2002. |

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**SEPTEMBER      30, 2005**

|         |                                                                               |                               |
|--------------|------------------------------------------------------------------------------------|------------------------------------|
|         | **STATSURE DIAGNOSTIC SYSTEMS,              INC.**                                 |
|    |                                                                          |                          |
|              |                                                 | /s/              Steve M. Peltzman |
|         | Steve M. Peltzman                                                                  |
|         | Chief                Executive Officer(principal                executive officer) |

|   |                                                                               |            |
|--------|------------------------------------------------------------------------------------|-----------------|
|        |                                                 | /s/ Leo Ehrlich |
|   | Leo              Ehrlich                                                           |
|   | Chief                Financial Officer(principal                financial officer) |

----